2024
National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 31: 9088-9099. PMID: 39322830, DOI: 10.1245/s10434-024-16107-w.Peer-Reviewed Original ResearchHR patientsLymph nodesRate of neoadjuvant chemotherapyHospital admissionNational patterns of careEmergency departmentDecrease wound complicationsNeoadjuvant chemo-Hospital re-admissionNeoadjuvant chemotherapyIn-hospital admissionRate of reconstructionPerioperative outcomesPostoperative hematomaComplication ratePostoperative complicationsWound complicationsHome recoveryPatterns of careBreast cancerMastectomyEmergency room visitsMultivariate analysisComplicationsPatients
2020
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapy
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regression
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsAssociation Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Shammas R, Cho E, Glener A, Poveromo L, Mundy L, Greenup R, Blackwell K, Hollenbeck S. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. Journal Of The American College Of Surgeons 2017, 225: 731-739.e1. PMID: 28985927, DOI: 10.1016/j.jamcollsurg.2017.08.023.Peer-Reviewed Original ResearchConceptsPostoperative wound breakdownBreast reconstructionReconstructive complicationsWound breakdownReconstructive operationsPropensity score-matched pairsMastectomy skin flap necrosisDuke University Medical CenterAdministration of trastuzumabPrimary study outcomeSkin flap necrosisLarger tumor sizePost-mastectomy reconstructionBreast reconstruction outcomesOccurrence of hematomaUniversity Medical CenterPertuzumab therapyChemotherapy regimenNeoadjuvant chemotherapyOperative interventionFlap thrombosisTrastuzumab therapySurgical outcomesTumor sizeFlap necrosisImpact of insurance status on treatment for stage 0-IV breast cancer.
Greenup R, Thomas S, Fayanju O, Hyslop T, Hwang E. Impact of insurance status on treatment for stage 0-IV breast cancer. Journal Of Clinical Oncology 2017, 35: 6532-6532. DOI: 10.1200/jco.2017.35.15_suppl.6532.Peer-Reviewed Original ResearchRisk of deathInsurance statusBreast cancerStage 0Private insuranceMultivariate Cox proportional hazards modelStage 1 breast cancerUninsured breast cancer patientsNational Cancer Data BaseCox proportional hazards modelUnilateral stage 0Receipt of chemotherapyReceipt of surgeryStage 4 diseaseReceipt of treatmentBreast cancer patientsProportional hazards modelBinary logistic regressionNeoadjuvant chemotherapyOncologic outcomesOverall survivalBilateral mastectomyMedian ageUninsured womenTreatment patternsRole of axillary node dissection after mastectomy with positive sentinel nodes.
Park T, Thomas S, Greenup R, Hwang E. Role of axillary node dissection after mastectomy with positive sentinel nodes. Journal Of Clinical Oncology 2017, 35: 554-554. DOI: 10.1200/jco.2017.35.15_suppl.554.Peer-Reviewed Original ResearchAxillary lymph node dissectionPositive sentinel nodesAdjuvant radiationNode dissectionSentinel nodesTumor sizeRadiation treatmentComparable overall survivalLymph node dissectionMedian tumor sizeNational Cancer DatabaseStage IV diseaseAxillary node dissectionBreast conservation therapyHazard of deathAxillary lymphadenectomyPositive SLNZ11 trialCause mortalityEndocrine therapyNeoadjuvant chemotherapyPositive nodesNegative patientsOverall survivalSentinel lymph
2012
Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer.
Greenup R, Bardia A, Buckley J, Niemierko A, Camp M, Coopey S, Gadd M, Schapira L, Taghian A, Smith B, Specht M. Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. Journal Of Clinical Oncology 2012, 30: 1122-1122. DOI: 10.1200/jco.2012.30.15_suppl.1122.Peer-Reviewed Original ResearchPathologic complete responseNeoadjuvant chemotherapyOverall survivalBreast cancerComplete responseYoung womenAdjuvant chemotherapyHazard ratioHER-2Stage IYoung breast cancer patientsTriple-negative breast cancerNeo-adjuvant chemotherapyTiming of chemotherapyBreast cancer patientsState tumor registryFinal pathologic reviewDeath certificate dataNegative breast cancerValuable surrogate markerOS ratesPathologic reviewSystemic therapyTumor RegistryDeath Index